转自：扬子晚报 扬子晚报网1月2日讯 （通讯员 扬文 记者 王国柱）2025年12月31日下午，扬子江药业集团2025年年终工 作会议暨职工代表大会在江苏泰州召开。会议全面总结集团2025年各项工作成效，科学谋划"十五五"时 期发展蓝图。泰州市委书记姜冬冬出席会议并讲话，他勉励扬子江药业集团发挥好领军作用，朝着世界 一流的医药健康产业集团稳步迈进，再攀高峰、再创佳绩，为"健康名城、幸福泰州"作出新的贡献。 徐浩宇作报告 泰州市领导陈力、张坤、杨芙蓉出席会议。扬子江药业集团党委书记、董事长、总裁徐浩宇作年终工作 报告。报告指出，扬子江药业集团坚定向新行、向高攀、向优转，在创新研发、智能制造、可持续发展 等领域取得新突破。创新成果密集推进：1.1类中药创新药益气通窍丸全国上市、1类化学创新药抗ED 盐酸妥诺达非片上市获批、抗失眠新药法赞雷生片完成NDA递交，全国重点实验室承接国家、省部级 重大科研项目140余项。 姜冬冬在讲话中对扬子江药业集团2025年取得的突出成绩给予充分肯定。他指出，新的一年是"十五 五"开局之年。希望扬子江药业集团在服务国家战略上打头阵，坚定信心、胸怀壮志，深度融入"健康中 国"战略，深挖 ...

Core Insights - Yangtze River Pharmaceutical Group has shown continuous improvement in operational innovation during the first half of 2023, despite a challenging external environment [1][2] - The company is focusing on a "health ecosystem" strategy and has achieved significant milestones in management, innovation, and corporate governance [1] Group 1: Operational Performance - In the first half of 2023, Yangtze River achieved a seven-star certification in the EFQM global award's first phase, making it the only pharmaceutical company in China to do so [1] - The company was recognized as one of the first batch of excellent intelligent factories in the country, indicating its advanced level in smart manufacturing [1] - The innovative traditional Chinese medicine product, Yiqi Tongqiao Wan, was launched nationwide, marking a significant achievement in treating allergic rhinitis [1] Group 2: Strategic Initiatives - The company is committed to the "health marketing" philosophy and is actively participating in national health initiatives, including the "Weight Management Year" campaign [2] - Yangtze River hosted its first Health Culture Festival and established the "Yangtze River Cultural Salon" to promote health culture [2] - The company has organized over 3,700 offline health activities as part of its "All Staff Sports Day" initiative [2] Group 3: Growth and Future Plans - The health sector and international business of Yangtze River have seen substantial growth, with year-on-year increases of 365% and 237%, respectively [2] - The company aims to prepare for the second phase of the EFQM global award assessment and is focusing on high-quality research and development projects [2] - Yangtze River is also exploring the application of AI in the acceptance of medicinal materials and is implementing 52 energy-saving and emission-reduction projects [2]

Core Viewpoint - The innovative traditional Chinese medicine (TCM) product Yiqi Tongqiao Wan has successfully completed phase III clinical trials and is now available for treating allergic rhinitis, with plans for a large-scale real-world study involving 10,000 samples to validate its clinical efficacy [1][3]. Group 1: Product Development and Efficacy - Yiqi Tongqiao Wan is developed by integrating modern medicinal components from the effective formula "Allergy Decoction" and employs modern pharmaceutical techniques [2]. - Clinical trial results show significant efficacy, with a nasal discharge symptom disappearance rate of 52.65% and a tear symptom disappearance rate of 80.97%. Additionally, 30% of patients did not experience a recurrence of rhinitis within a year after two weeks of treatment [3]. Group 2: Quality Control and Technological Integration - The quality of raw materials is crucial for modern pharmaceutical companies, and Yiqi Tongqiao Wan's 14 ingredients are sourced from high-quality regions and standardized cultivation bases [5]. - The production process utilizes digital technology for quality traceability throughout the entire supply chain, enhancing the stability and uniformity of the extract's quality [5][6]. Group 3: Market Expansion and Cultural Promotion - The company is expanding the application of TCM by developing diverse product lines, including health foods and beverages that incorporate TCM ingredients [8]. - Efforts to promote TCM culture include public health services and community engagement activities, aiming to enhance public understanding and acceptance of TCM [8].